Clinical Trial: Study of BMS-986168 in Patients With Progressive Supranuclear Palsy
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants With Progressive
Brief Summary: The purpose of this study is to determine the efficacy and safety of intravenously administered BMS-986168 in participants with Progressive Supranuclear Palsy.
Detailed Summary:
Sponsor: Bristol-Myers Squibb
Current Primary Outcome:
- Change in PSP (Progressive Supranuclear Palsy) Rating Scale [ Time Frame: Up to 52 Weeks ]Change from baseline
- Frequency of Adverse Events [ Time Frame: Up to 52 Weeks ]Numbers and Percentages
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Bristol-Myers Squibb
Dates:
Date Received: February 27, 2017
Date Started: April 24, 2017
Date Completion: June 30, 2020
Last Updated: May 2, 2017
Last Verified: May 2017